A Cell Reports study tied C9orf72-related ALS/FTD inflammation to a gut-bacterial product: inflammatory microbial glycogen appeared in 15 of 22 ALS fecal samples, 1 of 1 C9orf72-frontotemporal dementia sample, and 4 of 12 healthy controls.1 The result supports a narrower gene-by-microbial-product mechanism that makes C9orf72 loss of function more inflammatory. Research Highlights Human samples carried …
In 433 non-demented amyotrophic lateral sclerosis (ALS) patients, clinically significant anxiety was present in 18.2% for state anxiety and 13.9% for trait anxiety. The strongest predictor was not motor severity, cognition, or caregiver-rated behavior; it was depression, especially cognitive-affective depression symptoms.1 Research Highlights ALS anxiety was measurable but not universal: Aiello et al. found clinically …
Frontotemporal dementia (FTD) is a challenging and impactful neurodegenerative disease. Recent research offers new insights into its management, particularly regarding the effectiveness of pharmacological treatments. Highlights: High-Dose Oxytocin Shows Promise: High-dose oxytocin (72 international units) has been linked to significant improvements in neuropsychiatric symptoms and daily interactive activities in FTD patients. Piracetam Poses Risks: Contrarily, …
A 34-year-old man developed symptoms of frontotemporal dementia (FTD), a rare form of early-onset dementia, after using cannabis for two years. This case highlights the potential risks of long-term cannabis use on brain health, especially for vulnerable individuals. Key Facts: The 34-year-old man used cannabis for two years before experiencing personality changes and behavioral symptoms …